Company Description
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States.
The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.
It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform.
The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015.
Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Country | United States |
Founded | 2003 |
IPO Date | Sep 15, 2020 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 480 |
CEO | Leslie Trigg |
Contact Details
Address: 3052 Orchard Drive San Jose, California 95134 United States | |
Phone | 669 231 8200 |
Website | outsetmedical.com |
Stock Details
Ticker Symbol | OM |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $27.00 |
CIK Code | 0001484612 |
CUSIP Number | 690145107 |
ISIN Number | US6901451079 |
Employer ID | 20-0514392 |
SIC Code | 3845 |
Key Executives
Name | Position |
---|---|
Leslie L. Trigg | President, Chief Executive Officer and Chairman |
Nabeel Ahmed | Chief Financial Officer |
John L. Brottem J.D. | General Counsel and Secretary |
Marc Nash | Senior Vice President of Operations and Research & Development |
James S. Mazzola | Head of Investor Relations |
Laura Romike | Senior Vice President of Sales |
Amelia Merrill | Vice President of People Operations and Culture |
Dr. Michael Aragon M.D. | Chief Medical Officer |
Jennifer Sipple | Senior Vice President of Customer Experience |
Dinamarie Stefani | Senior Vice President of Regulatory Affairs and Quality Assurance |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 19, 2025 | 8-K | Current Report |
Feb 18, 2025 | 144 | Filing |
Feb 18, 2025 | 144 | Filing |
Feb 18, 2025 | 144 | Filing |
Feb 18, 2025 | 144 | Filing |
Feb 13, 2025 | S-3 | Registration statement under Securities Act of 1933 |
Feb 12, 2025 | SCHEDULE 13G/A | Filing |
Feb 4, 2025 | DEF 14A | Other definitive proxy statements |
Jan 31, 2025 | SCHEDULE 13G/A | Filing |
Jan 24, 2025 | 8-K | Current Report |